ArticleCardiology2026
Aortic Valve Calcification Scores versus CT-FFR: Prediction of Major Adverse Cardiovascular Events after Transcatheter Aortic Valve Replacement.
Article in Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aimed to assess the prognostic value of aortic valve calcification (AVC) score and CT angiography-derived fractional flow reserve (CT-FFR) for major adverse cardiovascular events (MACEs) after transcatheter aortic valve replacement (TAVR).
methodsIn this retrospective observational cohort study, we included patients with severe aortic valve diseases undergoing TAVR between February 2016 and April 2022. Patients were followed, and univariable and multivariate Cox regression were applied for outcome analysis using a composite endpoint including all-cause mortality, nonfatal myocardial infarction, unstable angina, heart failure rehospitalization. The incremental prognostic value of CT-FFR was also analyzed.
resultsA total of 251 patients were enrolled (mean age, 67 ± 10 years; 176 men). During a mean follow-up period of 36 months, 60 (23.9%) patients experienced MACE. AVC score ≥2,000 (hazard ratio [HR] = 1.714, 95% confidence intervals [CI]: 1.020, 2.882, p = 0.042) and CT-FFR ≤0.8 (HR = 3.248, 95% CI: 1.760, 5.996, p < 0.001) were independent predictors of MACE. The C statistics revealed that adding CT-FFR to the clinical risk factors alone or combined with AVC score provided incremental prognostic value for MACE after TAVR (C-index: 0.697 vs. 0.645 [p = 0.012]; and 0.710 vs. 0.672 [p = 0.030]).
conclusionAVC score and CT-FFR were associated with MACE in patients after TAVR, and CT-FFR presented incremental prognostic value for MACE beyond clinical risk factors alone or combined with AVC score. Therefore, CT-FFR may provide incremental prognostic information and requires prospective validation prior to routine implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.